Medea

Medea Biopharma is a Munich-based biotechnology company dedicated to developing next-generation phage-based therapies to address the global crisis of antimicrobial resistance. The company leverages a proprietary platform to engineer and optimize bacteriophages that specifically target and eliminate pathogenic bacteria while sparing the natural microbiome. Their primary focus is on treating chronic and life-threatening infections caused by multi-drug resistant organisms, such as Staphylococcus aureus and Pseudomonas aeruginosa. By combining advanced synthetic biology with phage research, Medea Biopharma aims to provide precise, effective alternatives to traditional antibiotics. The company is a spin-off from the Technical University of Munich and is backed by leading European venture capital firms.